Thus, our studies reveal mechanisms that underlie TL1A-DR3 antagonism as a potential source for therapeutics aimed at mitigating inflammation and fibrosis in IBD, as well as potentially other inflammatory/fibrotic diseases. This evidence concerns the gene TNFSF15 and inflammatory bowel disease.